| title = Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome 

 
A pharmacogenomic [[genome-wide association study]] (GWAS) reported that patients from the dal-OUTCOMES study bearing a protective allele at SNP rs1967309 in the ADCY9 gene may have benefited from dalcetrapib therapy.<ref>{{Cite journal|last=Tardif|first=Jean-Claude|last2=Rhéaume|first2=Eric|last3=Lemieux Perreault|first3=Louis-Philippe|last4=Grégoire|first4=Jean C.|last5=Feroz Zada|first5=Yassamin|last6=Asselin|first6=Géraldine|last7=Provost|first7=Sylvie|last8=Barhdadi|first8=Amina|last9=Rhainds|first9=David|date=2015-04-01|title=Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib|journal=Circulation: Cardiovascular Genetics|volume=8|issue=2|pages=372–382|doi=10.1161/CIRCGENETICS.114.000663|issn=1942-3268|pmid=25583994}}</ref> Changes in inflammation and cholesterol efflux capacity may in part explain the benefits associated with the protective genotype.<ref>{{Cite journal|last=Tardif|first=Jean-Claude|last2=Rhainds|first2=David|last3=Brodeur|first3=Mathieu|last4=Feroz Zada|first4=Yassamin|last5=Fouodjio|first5=René|last6=Provost|first6=Sylvie|last7=Boulé|first7=Marie|last8=Alem|first8=Sonia|last9=Grégoire|first9=Jean C.|date=2016-08-01|title=Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes|journal=Circulation: Cardiovascular Genetics|volume=9|issue=4|pages=340–348|doi=10.1161/CIRCGENETICS.116.001405|issn=1942-3268|pmc=4982759|pmid=27418594}}</ref> The Dal-GenE trial is currently validating these observations. This clinical trial is a randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in patients with recent acute coronary syndrome bearing the protective genotype.<ref>{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT02525939|title=Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|access-date=2016-12-02}}</ref>

 
<ref name=cortez2012>{{Citation|author=Michelle Fay Cortez |publication-date=November 5, 2012 |title=Roche’s Good Cholesterol Drug Shows Negative Side Effects |magazine=[[Bloomberg Businessweek]] |url=http://www.businessweek.com/news/2012-11-05/roche-s-good-cholesterol-drug-shows-negative-side-effects |accessdate=November 6, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20121108025333/http://www.businessweek.com/news/2012-11-05/roche-s-good-cholesterol-drug-shows-negative-side-effects |archivedate=November 8, 2012 |df= }}</ref>

 
<ref name=tfl2012>{{cite journal |author=Thomas F. Lüscher |author2=Stefano Taddei |display-authors=1 |title=Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial |journal=[[Eur. Heart J.]] |year=2012 |doi=10.1093/eurheartj/ehs019 |url=http://eurheartj.oxfordjournals.org/content/early/2012/02/16/eurheartj.ehs019.abstract |volume=33 |issue=7 |pages=857–865}}</ref>
